575 related articles for article (PubMed ID: 34622421)
21. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
Giannelos N; Ng C; Curran D
Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
[TBL] [Abstract][Full Text] [Related]
22. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
23. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
Parikh R; Singer D; Chmielewski-Yee E; Dessart C
Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
[TBL] [Abstract][Full Text] [Related]
25. Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology.
Tavares-Da-Silva F; Mahaux O; Van Holle L; Haguinet F; Seifert H; Stegmann JU
Drug Saf; 2020 Dec; 43(12):1223-1234. PubMed ID: 32862397
[TBL] [Abstract][Full Text] [Related]
26. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
[TBL] [Abstract][Full Text] [Related]
27. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
Lasagna A; Mele D; Bergami F; Alaimo D; Dauccia C; Alessio N; Comolli G; Pasi F; Muzzi A; Novelli V; Baldanti F; Pedrazzoli P; Cassaniti I
Hum Vaccin Immunother; 2023 Dec; 19(3):2288282. PubMed ID: 38037900
[TBL] [Abstract][Full Text] [Related]
28. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
[TBL] [Abstract][Full Text] [Related]
29. Herpes Virus Infections in Kidney Transplant Patients (HINT) - a prospective observational cohort study.
Hamm SR; Saini SK; Hald A; Vaaben AV; Pedersen NW; Suarez-Zdunek MA; Harboe ZB; Bruunsgaard H; Johansen IS; Larsen CS; Bistrup C; Birn H; Sørensen SS; Hadrup SR; Nielsen SD
BMC Infect Dis; 2023 Oct; 23(1):687. PubMed ID: 37845608
[TBL] [Abstract][Full Text] [Related]
30. Herpes zoster in Belgium: a new solution to an old problem.
Nikkels AF; Schoevaerdts D; Kauffmann F; Strubbe F; Bensemmane S
Acta Clin Belg; 2024 May; ():1-12. PubMed ID: 38781037
[TBL] [Abstract][Full Text] [Related]
31. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.
Janusz CB; Anderson TC; Leidner AJ; Lee GM; Dooling K; Prosser LA
Hum Vaccin Immunother; 2022 Nov; 18(5):2060668. PubMed ID: 35476029
[TBL] [Abstract][Full Text] [Related]
32. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.
Hentzien M; Bonnet F; Bernasconi E; Biver E; Braun DL; Munting A; Leuzinger K; Leleux O; Musardo S; Prendki V; Schmid P; Staehelin C; Stoeckle M; Walti CS; Wittkop L; Appay V; Didierlaurent AM; Calmy A
BMC Infect Dis; 2024 Mar; 24(1):329. PubMed ID: 38504173
[TBL] [Abstract][Full Text] [Related]
33. Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention.
Litt J; Cunningham AL; Arnalich-Montiel F; Parikh R
Infect Dis Ther; 2024 Jun; ():. PubMed ID: 38834857
[TBL] [Abstract][Full Text] [Related]
34. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.
Kim JH; Diaz-Decaro J; Jiang N; Hwang SJ; Choo EJ; Co M; Hastie A; Hui DSC; Irimajiri J; Lee J; Leung EM; Tang H; Tsuru T; Watson P; Wu Z; Yu CJ; Yuan Y; Zahaf T; Cunningham AL; Schuind A
Hum Vaccin Immunother; 2021 Jul; 17(7):2050-2057. PubMed ID: 33606577
[TBL] [Abstract][Full Text] [Related]
35. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
Min JY; Mwakingwe-Omari A; Riley M; Molo LY; Soni J; Girard G; Danier J
J Infect; 2022 Apr; 84(4):490-498. PubMed ID: 34963639
[TBL] [Abstract][Full Text] [Related]
36. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
Willis ED; Woodward M; Brown E; Popmihajlov Z; Saddier P; Annunziato PW; Halsey NA; Gershon AA
Vaccine; 2017 Dec; 35(52):7231-7239. PubMed ID: 29174682
[TBL] [Abstract][Full Text] [Related]
37. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
[TBL] [Abstract][Full Text] [Related]
38. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.
Hesse EM; Shimabukuro TT; Su JR; Hibbs BF; Dooling KL; Goud R; Lewis P; Ng CS; Cano MV
MMWR Morb Mortal Wkly Rep; 2019 Feb; 68(4):91-94. PubMed ID: 30703077
[TBL] [Abstract][Full Text] [Related]
39. Herpes Zoster Vaccines.
Harbecke R; Cohen JI; Oxman MN
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]